These patterns specifically justify exploring PD-1/CTLA4 inhibitors for high-risk HCC, particularly when combined with evasion-countering approaches.While the TIDE results and checkpoint profiles suggest treatment potential, TIDE’s predictive framework originated from melanoma and NSCLC studies with limited HCC validation. Here, CTLA4 is linked to non-small cell lung carcinoma.